Key points from article :
Treatment combined diabetes drugs GLP-1, GIP and glucagon.
Type 2 diabetes is a known risk factor for Alzhemier’s disease.
Reduction in nerve-cell-killing protein molecules was particularly interesting.
Treated mice also had lower levels of proteins which form plaques.
Other drugs have shown promise in mice models of Alzheimer’s disease and then failed in human trials.
The study was published in the Brain Research journal.
